Movatterモバイル変換

[0]ホーム
URL:

AU2024231397A1 - Therapy for bladder cancer - Google Patents

Therapy for bladder cancer

Info

Publication number
AU2024231397A1
AU2024231397A1AU2024231397AAU2024231397AAU2024231397A1AU 2024231397 A1AU2024231397 A1AU 2024231397A1AU 2024231397 AAU2024231397 AAU 2024231397AAU 2024231397 AAU2024231397 AAU 2024231397AAU 2024231397 A1AU2024231397 A1AU 2024231397A1
Authority
AU
Australia
Prior art keywords
bladder cancer
therapy
composition
relates
bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024231397A
Inventor
Aslak Godal
Gry Stensrud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASAfiledCriticalPhotocure ASA
Publication of AU2024231397A1publicationCriticalpatent/AU2024231397A1/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The present invention relates to the treatment of bladder cancer. In particular, it relates to a composition comprising hexyl 5-ALA ester (HAL), or a pharmaceutically acceptable salt thereof, for use in a method of therapy for bladder cancer, wherein said method comprises instillation of said composition into the bladder of a patient, and wherein said method is not a method of photodynamic therapy.
AU2024231397A2023-03-072024-03-06Therapy for bladder cancerPendingAU2024231397A1 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
EP23160601.32023-03-07
EP231606012023-03-07
PCT/EP2024/055897WO2024184417A1 (en)2023-03-072024-03-06Therapy for bladder cancer

Publications (1)

Publication NumberPublication Date
AU2024231397A1true AU2024231397A1 (en)2025-09-25

Family

ID=85510919

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2024231397APendingAU2024231397A1 (en)2023-03-072024-03-06Therapy for bladder cancer

Country Status (2)

CountryLink
AU (1)AU2024231397A1 (en)
WO (1)WO2024184417A1 (en)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7530461B2 (en)1995-03-102009-05-12Photocure AsaEsters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
EP0820432B1 (en)1995-03-102001-06-13PhotoCure ASAEsters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
DK2206517T3 (en)2002-07-032023-11-06Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
GB0406917D0 (en)2004-03-262004-04-28Photocure AsaCompounds
CN102131828B (en)2007-06-182015-06-17默沙东有限责任公司 Antibody against human programmed death receptor PD-1
US8168757B2 (en)2008-03-122012-05-01Merck Sharp & Dohme Corp.PD-1 binding proteins
PT4209510T (en)2008-12-092024-04-02Hoffmann La RocheAnti-pd-l1 antibodies and their use to enhance t-cell function
CN103096884B (en)2010-09-142017-11-03学校法人东京农业大学 Effect enhancer of cancer thermotherapy
TWI835048B (en)2011-08-012024-03-11美商建南德克公司Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2012344260B2 (en)2011-11-282017-09-07Merck Patent GmbhAnti-PD-L1 antibodies and uses thereof
CN104271601B (en)2012-05-312020-02-04霍夫曼-拉罗奇有限公司Methods of treating cancer using PD-1 axis binding antagonists and VEGF antagonists
JP6280117B2 (en)2012-08-032018-02-14フォトキュア エイエスエイ Compound
GB201522311D0 (en)2015-12-172016-02-03Photocure AsaUse
DK3389716T3 (en)2015-12-172022-04-11Photocure Asa METHOD OF PHOTODYNAMIC THERAPY (PDT) FOR BLADDER CANCER
GB201522309D0 (en)2015-12-172016-02-03Photocure AsaUse

Also Published As

Publication numberPublication date
WO2024184417A1 (en)2024-09-12

Similar Documents

PublicationPublication DateTitle
IL189546A0 (en)Therapy for the treatment of disease
MXPA04000647A (en)5-aminolevulinic acid and esters, in combination with another phtosensitizer, as photosensitizing agents in photochemotherapy, and their uses in treating wounds.
WO2020205473A8 (en)Compositions and methods for the treatment of kras associated diseases or disorders
WO2002004008A3 (en)Methods of therapy with thrombin derived peptides
WO2006035204A3 (en)Combination comprising zd6474 and an imatinib
EP4585269A3 (en)Methods for cancer therapy
EP4494701A3 (en)New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
WO2002102743A3 (en)DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO2002039999B1 (en)Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
AU2024231397A1 (en)Therapy for bladder cancer
WO2000006136A3 (en)Therapeutic combination of polyamine with an anticancer agent
WO2022026622A3 (en)Treatment of viral diseases
WO2001054678A3 (en)Combination therapy for cancer
WO2023019095A3 (en)Momelotinib combination therapy
EE200200549A (en) Split dose therapy with vascular damaging activity
BRPI0412450A (en) methods for producing an antiangiogenic reducing and / or vascular permeability effect in a warm-blooded animal such as a human, and for treating a cancer, pharmaceutical composition, kit, and use of azd2171 or a pharmaceutically salt acceptable thereof and zd6126 or a pharmaceutically acceptable salt thereof
CA2469702A1 (en)Darifenacin for use in the treatment of urgency induced by overactive bladder
WO2004112565A3 (en)Diagnosis and treatment of liver, pulmonary and cardiac fibrosis
AU6470400A (en)Nitroxy derivatives of (r) and (s)-carnitine
PT1183046E (en) AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF CARDIOVASCULAR DISEASES
CA2515259A1 (en)Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
AU2024211950A1 (en)Fatty acid compounds and methods of use
WO2024115525A3 (en)Novel chlorin e6 analogues
MXPA05011418A (en)Method for administration of troxacitabine.
IL313067A (en)Methods of treating neurological disorders
[8]ページ先頭
©2009-2025 Movatter.jp